Ibrutinib is a type of drug used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is a type of targeted therapy, meaning it works by targeting specific proteins in cancer cells. It is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), an enzyme involved in the growth and survival of cancer cells. Ibrutinib works by blocking the activity of BTK, which helps to stop the growth and spread of cancer cells. Ibrutinib is approved by the US Food and Drug Administration (FDA) for the treatment of CLL and SLL. It is also approved for the treatment of Waldenström's macroglobulinemia, a type of non-Hodgkin's lymphoma. It is available in both oral and intravenous forms. Ibrutinib is marketed by several companies, including Janssen Pharmaceuticals, AbbVie, and Pharmacyclics. It is also available as a generic drug in some countries. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
